3[1]Chobanian AV,Bakris GL,Black HR,et al.The Seventh report of the Joint National Committee On prevention,detection,evaluation,and treatment of high blood pressure[J].JAMA,2003,289(19):2560-2572. 被引量：1
4[2]European Society of hypertension-European Society of Cardiology guidelines Committee 2003 European Society of hypertension-European society of Cardiology guidelines for management of arterial hypertension[J].J hypertens,2003,21(6):1011-1053. 被引量：1
5[4]Safar ME,hypothesis on isalated Systolic hypertension in the eldery[J].J hum hypertens,1999,13:813-815. 被引量：1
6[5]Ishanov A,Okeamoto H,Yoneyak,et al.angiotensinogen gene Polymorphism in Japanese Patients with hypertrophic Cardiomyopathy[J].Am heart J,1997,133:184-189. 被引量：1
7[6]Sethi AA,Nordestguard BG,Agerholm-Larsen B,et al.Angiotensinogen Polymorphisms and elevated blood pressure in the general polulation:the Capenhagen City Heart Study[J].Hypertension,2001,37(3):875-881. 被引量：1
8[7]SHEP Cooperative Research group.Prevention of Strokce by antihypertensione drug treatment in olderly Pressure with:silated systolic hypertension final results of the Systolic hypertonsion in the Elderly program (SHEP)[J].JAMA,1991,265:3255-3264. 被引量：1
9[8]Hansson JA,Zanchettei A,Carruthers SG,et al.Effects of intensive blood-Pressare Lowering and Low-dose aspirin in Patients with hypertension:Principal resurts of the hypertension Optimal treatment(HOT)rondomized trial[J].Lancet,1998,351(9118):1755-1762. 被引量：1
10[10]Pepine CJ,Handberg EM,Cooper-DeHoff RM,et al.Calcium antigonist VS a non-CaSlcium antagonist hypertension treatment Strategy for patients with Coronary artery disease.the international Varapamil-treatment Study (INVEST)randomized Controlled trial[J] JAMA,2003,290(21):2805-2816. 被引量：1
